DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: RAPAFLO

Summary for Tradename: RAPAFLO

Patents:1
Applicants:1
NDAs:1
Suppliers: see list2
drug
patent expirations by year for
 RAPAFLO

Pharmacology for Tradename: RAPAFLO

Clinical Trials for: RAPAFLO

Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Status: Completed Condition: Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
Status: Active, not recruiting Condition: Benign Prostatic Hyperplasia

Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
Status: Completed Condition: Benign Prostatic Hypertrophy

Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
Status: Completed Condition: Benign Prostatic Hyperplasia

A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Status: Completed Condition: Nocturia; Prostatic Hyperplasia

Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Status: Recruiting Condition: Nocturia; Benign Prostatic Hyperplasia

A Dose-finding Study of Silodosin in Patients With Urinary Calculi
Status: Completed Condition: Urinary Calculus

Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder
Status: Completed Condition: Neurogenic Bladder; Voiding Dysfunction

Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
Status: Completed Condition: Benign Prostatic Hyperplasia

Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
Status: Not yet recruiting Condition: Kidney Stones

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
RAPAFLO
silodosin
CAPSULE;ORAL022206Oct 8, 2008RXNo<disabled><disabled>
Watson Labs
RAPAFLO
silodosin
CAPSULE;ORAL022206Oct 8, 2008RXNo5,387,603<disabled>YY<disabled>
Watson Labs
RAPAFLO
silodosin
CAPSULE;ORAL022206Oct 8, 2008RXYes<disabled><disabled>
Watson Labs
RAPAFLO
silodosin
CAPSULE;ORAL022206Oct 8, 2008RXYes5,387,603<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RAPAFLO

Drugname Dosage Strength RLD Submissiondate
silodosinCapsules4 mg and 8 mgRapaflo10/9/2012

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc